Mikael Dolsten, MD, PhD, recently retired from his 16-year tenure as chief scientific officer and president of Pfizer Research & Development. 

Dolsten oversaw the regulatory approval of over 36 medicines and vaccines, while advancing more than 150 drug candidates into clinical studies. He championed breakthrough innovations across small-molecule medicines, biotherapeutics, gene therapies, and vaccines. 

His leadership experience includes serving as president of Wyeth Research, executive vice president and head of worldwide research at Boehringer Ingelheim, and Global VP at AstraZeneca managing cardiovascular, metabolic, and GI R&D. Earlier, he led research at Astra Draco (pulmonary & inflammation) and headed immunology-oncology at Pharmacia, Sweden. 

Dolsten currently sits on the public boards of Agilent Technologies, Novo Nordisk and Rocket Pharmaceuticals. He is chairman, board director or advisor in numerous private biotech companies, and in the life science investment VC / PE companies Google Ventures, Blackstone,  Canaan Partners,  Formation Bio, PartnersGroup and Canadian Investment Bank. 

His affiliations include the Scripps Research Institute, the Foundation for the NIH, Research America and membership of the Royal Swedish Academy of Engineering Sciences. 

With over 160 scientific publications and numerous patents, Dolsten holds both a PhD in tumour immunology and an MD from the University of Lund, Sweden, where he serves as a visiting professor.